EMED Technologies

EMED Technologies

Healthcare services for population health management

About EMED Technologies

Simplify's Rating
Why EMED Technologies is rated
C
Rated C on Competitive Edge
Rated B on Growth Potential
Rated D+ on Differentiation

Industries

AI & Machine Learning

Healthcare

Company Size

N/A

Company Stage

Late Stage VC

Total Funding

$22M

Headquarters

Chicago, Illinois

Founded

1987

Overview

eMed focuses on improving population health management, particularly through weight loss programs and chronic care for conditions such as obesity and type 2 diabetes. The company offers its GLP-1 Weight Management Program as a health benefit to other organizations, helping them enhance the health of their employees while also managing healthcare costs. eMed's approach includes the use of its proprietary "Empathetic AI" to support these health programs. Recently, eMed expanded its operations in the UK by acquiring the assets of Babylon Health, allowing it to continue providing healthcare services to former Babylon members. This B2B model sets eMed apart from competitors by emphasizing corporate wellness and targeted health solutions.

Simplify Jobs

Simplify's Take

What believers are saying

  • eMed's acquisition of Science 37 enhances patient access and accelerates study enrollment.
  • Collaboration with Aon reduces medical spend and hospitalization risks for obesity management.
  • Expansion into the UK market strengthens eMed's international presence and service delivery.

What critics are saying

  • Integration challenges with Science 37 may disrupt operations and delay merger benefits.
  • Cultural challenges in the UK may affect service delivery and customer satisfaction.
  • Reliance on AI solutions may lead to data privacy concerns and regulatory scrutiny.

What makes EMED Technologies unique

  • eMed specializes in B2B healthcare, focusing on weight loss and chronic care.
  • The company uses proprietary 'Empathetic AI' for personalized population health management.
  • eMed's GLP-1 Weight Management Program is a unique health benefit for organizations.

Help us improve and share your feedback! Did you find this helpful?

Funding

Total Funding

$22M

Above

Industry Average

Funded Over

1 Rounds

Notable Investors:
Late VC funding comparison data is currently unavailable. We're working to provide this information soon!
Late VC Funding Comparison
Coming Soon

Company News

PR Newswire
May 5th, 2025
Emed Announces Collaboration With Aon To Provide A Digital Glp-1 Benefit Program For Aon Colleagues

Partnership provides virtual clinical support with data driven measurement to improve adherence for obesity managementMIAMI, May 5, 2025 /PRNewswire/ -- eMed®, the leading Population Health technology platform in remote chronic care management and 24/7/365 live care, today announced an industry-changing collaboration with leading global professional services firm, Aon , to provide GLP-1 obesity management services for the company's U.S. employees.This collaboration builds off the momentum from Aon's recently released findings showing a seven percentage point reduction in the growth of medical spend in the second year of GLP-1 therapy, and a 44 percent reduction in risk of hospitalizations caused by major adverse cardiovascular events with adherent GLP-1 utilization. Both eMed and Aon are committed to improving population health by accessible, personalized, and effective healthcare solutions that support better health outcomes and address critical issues such as obesity, diabetes, and related comorbidities."We are thrilled to collaborate with Aon to bring our cutting-edge platform to their employees," said Dr. Patrice Harris, CEO of eMed. "Our platform is a science-based, all-in-one solution proven to deliver superior health outcomes for participants, while enabling employers to manage their spend on GLP-1s. Together with Aon, we're not just offering access to GLP-1s; we're ensuring they are used effectively to improve long-term employee health outcomes as demonstrated by Aon's groundbreaking analysis.""Our findings show that GLP-1s, when combined with holistic support like nutrition, exercise and mental health resources, can deliver lasting health improvements

Morningstar
May 5th, 2025
eMed Announces Collaboration with Aon to Provide a Digital GLP-1 Benefit Program for Aon colleagues

eMed announces collaboration with Aon to provide a digital GLP-1 benefit Program for Aon colleagues PR newswire MIAMI, May 5, 2025.

Refresh Miami
Feb 15th, 2024
Scaling The Impact And A Deep Data Analysis Are Ahead For Miami Tech Works’ Year 2

By Nancy DahlbergTraining at least a thousand people from Miami’s underrepresented communities for careers in technology in the next couple of years is a big goal, but together, a coalition laser-focused on the mission has proven Miami is up to the challenge. As Miami Tech Works and its innovative Miami Tech Talent Coalition enter year two, they took an opportunity to celebrate a productive first year and set the stage for what’s coming next: a strategic push to scale up the impact, backed by a thorough data analysis. For those not involved (yet), Miami Tech Works is backed by a $10 million grant over three years from the Biden Administration’s Good Jobs Challenge program to fuel Miami’s tech talent pipeline by creating new pathways for the county’s underserved population and connecting them with programs to learn, upskill and reskill. The Miami Tech Talent Coalition is an unprecedented collaboration of employers, academia and community organizations to do just that. Nearly 200 community members turned out for the 1-year anniversary event at Miami Dade College’s Chapman Conference Center last week. Terri-Ann Brown, Grant Director for Miami Tech Works, shared that although the grant period ends in 2025, the goal is to create sustainable programs and processes that will fuel the pipeline for years to come.  The Miami Tech Talent Coalition can facilitate those connections to fuel the pipeline, but “we need employers, academic institutions and community organizations around the table being open and honest about what Miami has in terms of assets, challenges and opportunities… and that’s what Miami Tech Works and the Tech Talent Coalition is here to do,” said Brown.Terri-Ann Brown, Grant Director of Miami Tech Works. First up, checking in on progress: In the past year, the Miami Tech Talent Coalition’s four working groups with 251 members have had 42 meetings and participated in five community-wide gatherings to share insights and challenges. But it wasn’t just talk. Several pilot projects were launched, tested and scaled successfully, including four sprinternships, and students were connected with technical assistance workshops and skills training at universities or bootcamps by BrainStation and 4Geeks Academy

GlobeNewswire
Jan 29th, 2024
Science 37 To Be Acquired By Emed, Expanding Access To Patients And Accelerating Enrollment

RESEARCH TRIANGLE PARK, N.C., Jan. 29, 2024 (GLOBE NEWSWIRE) -- Science 37 Holdings, Inc. (Nasdaq: SNCE) (the “Company” or “Science 37”), the clinical research industry’s leading MetasiteTM, today announced that it has entered into a definitive merger agreement to be acquired by eMed, LLC (“eMed”), the leader in on-demand virtual care and treatment for consumers. With the most authoritative in-home testing and treatment solution available across a variety of indications, the largest real-time network of certified remote proctors, and Test-to-TreatTM technology that streamlines the patient enrollment process, eMed brings significant resources to enhance Science 37’s ability to access unique patients, enroll studies faster, and ensure long-term sustainability. The transaction, which has been unanimously approved by Science 37 Board of Directors, is valued at an equity value of approximately $38 million and will be structured as an all-cash tender offer to acquire all outstanding shares of Science 37. Under the terms of the agreement, eMed, through its wholly owned subsidiary, will commence a tender offer to acquire all outstanding shares of Science 37 common stock for $5.75 in cash per share, representing a premium of approximately 21.3% over Science 37’s closing share price on the 26th of January, 2024, the last full trading day prior to the transaction announcement

Fierce Biotech
Jan 29th, 2024
Decentralized trial company Science 37 to be acquired by eMed in $38M deal

Decentralized trial company Science 37 to be acquired by eMed in $38M deal.

Recently Posted Jobs

Sign up to get curated job recommendations

EMED Technologies is Hiring for 7 Jobs on Simplify!

Find jobs on Simplify and start your career today

đź’ˇ
Don't see your dream role? Check out thousands of other roles on Simplify. Browse all jobs →